NCT05505006 is a Phase 4 clinical trial of Ferric Carboxymaltose Injection in Anemia, sponsored by Azienda Ospedaliera Universitaria Integrata Verona.

Who is sponsoring NCT05505006?

NCT05505006 is sponsored by Azienda Ospedaliera Universitaria Integrata Verona.

What drugs are being tested in NCT05505006?

Interventions in NCT05505006: Ferric Carboxymaltose Injection, Folic acid, B12.

What condition does NCT05505006 study?

NCT05505006 studies Anemia, Tumor.

Is NCT05505006 still recruiting?

NCT05505006 is currently status unknown. Last updated 19 August 2022.

Last reviewed 2022-08-19 · How we verify

NCT05505006

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Management of Preoperative Anaemia in Surgical Oncology

Status unknown Phase 4 Last updated 19 August 2022

What this trial tests

Phase 4 trial testing Ferric Carboxymaltose Injection in Anemia in 500 participants. Status unknown.

Timeline

2 March 2021

Primary endpoint
13 August 2024

13 August 2024

Quick facts

Lead sponsor	Azienda Ospedaliera Universitaria Integrata Verona
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	500
Start date	2 March 2021
Primary completion	13 August 2024
Estimated completion	13 August 2024
Sites	1 location across Italy

Drugs / interventions tested

Ferric Carboxymaltose Injection — full drug profile →
Folic acid (FOLIC ACID) — full drug profile →
B12 — full drug profile →

Conditions studied

Anemia — all drugs for Anemia →
Tumor — all drugs for Tumor →

Sponsor

Azienda Ospedaliera Universitaria Integrata Verona — full company profile →

Who can join

18 and older, any sex, with Anemia or Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Preoperative anemia is detrimental in surgical patients, and its treatment with transfusions can further worsen outcomes, including increased hospital stay and mortality. Transfusions are also highly costly. In 2010, the World Health Organization endorsed the adoption of Patient Blood Management (PBM) programs, i.e., patient-centered multidisciplinary activities, including recognition and treatment of preoperative anemia. While the latter has been proved effective in reducing transfusions in setting like elective orthopedic surgery, widespread adoption is still lacking. Moreover, little is known about surgical oncology, a particular setting posing unique challenging. This change-promoting project attempts to fill this knowledge gap by establishing a multidisciplinary team aimed at optimal management of preoperative anemia in hepatobiliary/pancreas/gastrointestinal/renal surgical oncology. The primary endpoint is the reduction of transfusions, along with safer patient outcomes as compared to the historical series.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ferric Carboxymaltose Injection

Trials testing the same drug.

NCT06895993 — Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants · Phase 1 · completed
NCT06080555 — Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia · Phase 1 · completed
NCT04510870 — Iron Deficiency as an Ignored Cause of Infertility · Phase 4 · unknown

Other recruiting trials for Anemia

Currently open trials in the same condition.

NCT07422480 — A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myel · Phase 3 · recruiting
NCT06968936 — Long-term Outcomes Sub-Study of Preoperative Combined Iron Therapy · NA · recruiting
NCT07328191 — Quality of Life-Guided Transfusion in Refractory MDS or AML · NA · recruiting
NCT07315295 — Maximizing the Benefits of Iron in Ready-to-Use Therapeutic Foods for Malnourished Children in Kenya · NA · recruiting
NCT07400796 — Assessing Health System Readiness for Scaling Antenatal MMS in Cambodia · recruiting

Other Azienda Ospedaliera Universitaria Integrata Verona trials

Trials by the same sponsor.

NCT07325877 — Supra-papillary Versus Trans-papillary Biliary Stenting in Malignant Peri-hilar Stenosis · NA · not yet recruiting
NCT07289035 — Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators. · Phase 2 · not yet recruiting
NCT07186582 — Verona Coronary Physiology Interventional Registry · active not recruiting
NCT06820541 — Gallbladder Stenting in FC-SEMS · NA · not yet recruiting
NCT07338708 — Visual Outcomes and Quality of Life After Vivity EDOF IOL Implantation in Early-Stage Keratoconus · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05505006 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda Ospedaliera Universitaria Integrata Verona
Last refreshed: 19 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05505006.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing